Danielle Boyle: Patient Voices Transform Progress in ITP Research and Care with ISTH
Danielle Boyle, Founder and CEO of ITP Australia and New Zealand, shared International Society on Thrombosis and Haemostasis (ISTH)’s post on LinkedIn, adding:
“I’m incredibly grateful to ISTH for sharing this member spotlight and for recognising the importance of patient voices in ITP research and care.
Founding ITP Australia and New Zealand has shown me, time and time again, that meaningful progress happens when patients, clinicians and researchers work together.
Lived experience brings context, clarity and humanity to the data, and it’s often the missing piece that helps shape research questions, treatment priorities and real ‑ world outcomes.
Hearing the stories, challenges and insights from people living with ITP is what drives this work forward.
Their voices don’t just inform research; they transform it.
Thank you to the International Society on Thrombosis and Haemostasis (ISTH) for highlighting the value of patient ‑ led organisations and for continuing to champion collaboration across the global haematology community.
I’m proud to be a member and part of a network that understands the power of partnership and the impact of listening deeply to the people at the heart of this condition.
- Grateful for the recognition.
- Grateful for the community.
- Grateful for the opportunity to keep pushing for better outcomes.”
International Society on Thrombosis and Haemostasis (ISTH) , shared a post on LinkedIn:
“Meet ISTH member Danielle Boyle, founder and CEO of ITP Australia and New Zealand.
In this video, she highlights the powerful role patient voices play in shaping meaningful research and improving outcomes for the ITP community.
We’re always so inspired to hear about the amazing work that our members are doing across the globe! ”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Oct 25, 2026, 17:43Jan Sloves: Femoral Vein Aneurysm and Chronic Venous Obstruction
-
Oct 25, 2026, 17:31Kasimu Hussaini: Blood Component Therapy From Whole Blood to Targeted Treatment
-
Oct 25, 2026, 17:23Zahra Safarzadeh: When Low Factor VII Activity and Reduced VWF Antigen Coexist
-
Oct 25, 2026, 17:17Anubhav Joshi: Evans Syndrome in CLL A Differential Diagnosis to Remember
-
Oct 25, 2026, 17:04Tehila Alter: Tracking Hematopoietic Cell Engraftment in Bone Marrow Using CEST MRI
-
Oct 25, 2026, 16:45Shauna Riley։ First Guidelines for Hemoglobin SC Disease
-
Oct 25, 2026, 16:26Heghine Khachatryan: Patient Safety and Clinical Judgment in Platelet Transfusion Decisions
-
Oct 25, 2026, 16:13Funmi (Vanessa) Ullam: From Lived Experience to Research and Innovation in Sickle Cell Care
-
Oct 25, 2026, 15:13Franky Biles: Celebrating Diversity and Driving Inclusion Through Representation